Molndal, Sweden

Tore Skjaret

USPTO Granted Patents = 4 



Average Co-Inventor Count = 6.1

ph-index = 3

Forward Citations = 148(Granted Patents)


Location History:

  • Mölndäl, SE (2007)
  • Mölndal, SE (2008)
  • Molndal, SE (2006 - 2011)

Company Filing History:


Years Active: 2006-2011

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Tore Skjaret

Introduction

Tore Skjaret is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of cholesterol absorption inhibitors. With a total of 4 patents to his name, Skjaret's work has the potential to impact the treatment of hyperlipidaemia.

Latest Patents

Skjaret's latest patents include innovative compounds such as 2-azetidinone derivatives. These compounds are described as cholesterol absorption inhibitors for the treatment of hyperlipidaemia. The patents detail processes for their manufacture and pharmaceutical compositions containing these compounds. Another significant patent involves diphenylazetidinone derivatives, which also serve as cholesterol absorption inhibitors. These compounds are similarly described with processes for their manufacture and potential applications in treating disorders of lipid metabolism.

Career Highlights

Tore Skjaret is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to focus on developing new therapeutic solutions that address critical health issues related to lipid metabolism.

Collaborations

Skjaret has collaborated with notable colleagues such as Ingemar Starke and Malin Anita Lemurell. These collaborations have likely contributed to the advancement of his research and the successful development of his patented innovations.

Conclusion

Tore Skjaret's contributions to the field of pharmaceuticals, particularly in cholesterol absorption inhibitors, highlight his innovative spirit and dedication to improving health outcomes. His work continues to pave the way for advancements in the treatment of hyperlipidaemia.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…